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Abstract: The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, 
panitumumab, represents a signiﬁ  cant advance in the treatment of colorectal cancer. The strat-
egy to target this receptor is based on sound cancer biology demonstrating its essential role in 
colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and 
thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected 
toxicities have become more apparent, raising concerns of how readily panitumumab can suc-
ceed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials 
that help our understanding of its optimal use in colorectal cancer treatment.
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Colorectal cancer (CRC)
Colorectal cancer ranks second in overall cancer deaths for men and women in the 
US with 148,810 new cases diagnosed and roughly 50,000 fatalities expected in 2008 
(Jemal et al 2008). Approximately 40% of these patients will develop metastatic 
disease and require systemic treatment. Advances in the number and types of active 
chemotherapy agents in colorectal cancer have been witnessed, although their optimal 
use remains to be established. Their initial evaluation in the metastatic setting will 
allow subsequent testing in earlier stage disease with the potential of curing a greater 
number of colorectal cancer patients.
Epidermal growth factor receptor
The epidermal growth factor receptor (EGFR; HER1 or c-ErbB-1) is a member of the 
HER family of receptor tyrosine kinases (TKs; including HER2, HER3, and HER4) 
(Citri and Yarden 2006). The EGFR is a transmembrane receptor with an intracellular 
TK domain that is activated by several growth factors, mainly EGF and transforming 
growth factor-α. With ligand binding, receptor dimerization occurs, and the receptor 
is activated via autophosphorylation of the associated TK domain. An intracellular 
signal transduction cascade is initiated with the subsequent phosphorylation of Ras, 
and other downstream signaling pathways, including the mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol- 3-kinase (PI3K)/AKT cascades. Ultimately, 
transcriptional activity is increased and multiple biologic processes are activated such as 
anti-apoptosis, chemotherapy resistance, angiogenesis, and metastasis (Baselga 2001). 
The EGFR is constitutively expressed in many human cancers, including 60%–80% 
of CRCs. Over-expression of EGFR correlates with poor prognosis, increased risk of 
metastasis, and drug resistance (Mendelson 2002). The malignant processes regulated 
by EGFR highlight the inhibition of receptor function as a potential therapeutic 
approach in colorectal cancer. Biologics: Targets & Therapy 2008:2(2) 224
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The development of EGFR inhibitors has led to the 
emergence of two classes of compounds: (1) monoclonal 
antibodies (MoAbs) directed against the extracellular domain 
of the EGFR (eg, cetuximab, panitumumab [ABX-EGF], and 
matuzumab [EMD 7200]); and (2) speciﬁ  c small-molecule 
inhibitors of the intracellular TK domain of EGFR (eg, 
erlotinib and geﬁ  tinib). In general, the latter class of com-
pounds, unlike in lung cancer, have shown minimal activity 
in colorectal cancer. This is largely due to the low incidence 
of mutations in the ATP site of the EGFR TK domain (0.34% 
or 1 mutated tumor in 293 analyzed) (Barber et al 2004).
The ﬁ  rst monoclonal antibody to demonstrate activity in 
colorectal cancer was cetuximab. It is a chimeric immuno-
globulin G (IgG1) monoclonal antibody consisting of human 
and murine sequences. The IgG1 subclass, in comparison 
with other IgG subclasses, can elicit antibody-dependent 
cellular cytotoxicity (ADCC) which theoretically contributes 
an immune-mediated anti-cancer effect. The murine peptide 
sequences are noteworthy as they introduce the risk of hyper-
sensitivity reactions; about 2% of patients experience grade 
4 anaphylaxis. This can be considerably higher, 21%, in 
certain geographic regions (O’Neil et al 2007). In addition, 
human anti-mouse antibodies against cetuximab can also be 
generated which could potentially inactivate the agent upon 
subsequent administrations. Cetuximab was approved in the 
US as a single agent or in combination with irinotecan for 
the treatment of EGFR-positive metastatic CRC refractory 
to irinotecan-based treatment (Cunningham et al 2004; Saltz 
et al 2004). This approval was based on several studies that 
demonstrated a unique ability of cetuximab to reverse irinote-
can resistance. More recent trials have shown cetuximab to be 
superior in terms of progression-free survival (PFS) and over-
all survival (OS) vs best supportive care in patients refractory 
to multiple lines of therapy (Jonker et al 2007). In addition, 
when used in the ﬁ  rst-line or second-line settings, addition 
of cetuximab to chemotherapy results in improvements in 
PFS (Sobrero et al 2008; Van Cutsem et al 2007a).
These early trials with cetuximab served as proof-of-
principle in validating the use of anti-EGFR monoclonal 
antibodies in the treatment of CRC. This success led to 
the development and emergence of successive monoclonal 
antibodies that were humanized and less likely to induce 
anti-mouse directed hypersensitivity reactions. An improved 
safety proﬁ  le without any loss in efﬁ  cacy was presumed 
which would allow these subsequent generation compounds 
to be fully interchangeable into chemotherapeutic regimens 
in which cetuximab had previously demonstrated beneﬁ  t. 
Unfortunately, these predictions were not validated in recent 
trials as unexpected, excess toxicities were encountered, as 
discussed below.
Panitumumab
Panitumumab is a high-afﬁ  nity (Kd = 5 × 10–11 M), fully 
human IgG2 monoclonal antibody with speciﬁ  city for the 
ligand-binding region of EGFR (Yang et al 2001). This rep-
resents an approximate 8-fold greater afﬁ  nity compared with 
cetuximab (Kd = 0.39 nM). The binding of panitumumab to 
EGFR completely blocks its association with ligands and 
activation of downstream kinase cascades. Panitumumab 
was constructed using XenoMouse® technology, a geneti-
cally engineered mouse whose immunoglobulin heavy and κ 
light chain loci are substituted with human immunoglobulin 
genes. Unlike cetuximab, panitumumab contains no murine 
protein sequences and thereby signiﬁ  cantly reduces the risk 
for hypersensitivity reactions.
The antineoplastic effects of panitumumab have been 
demonstrated in mouse models using xenografts from various 
tumor types (Yang et al 2001; Foon et al 2004). Panitumumab 
prevents xenograft formation and completely eradicates 
established tumors (as large as up to 1.2 cm3). When pani-
tumumab is combined with chemotherapeutic agents, such 
as platinums, inhibition of tumor growth and eradication of 
carcinoma cells in in vitro and in vivo models has also been 
demonstrated. In addition, the inhibition of tumor growth is 
sustained for up to an impressive 8 months after discontinu-
ation of therapy (Baselga and Mendelson 1997).
Early clinical evaluation included a phase I study 
(Weiner et al 2005) of panitumumab that revealed the agent 
to be active in several advanced solid tumors, in particular, 
metastatic CRC. In the trial, sequential cohorts of patients 
with EGFR-expressing cancers (at least 1+ in  10% of 
tumor cells) were administered 4 infusions of panitumumab 
that varied in dosage and treatment schedule. In each 
case, the drug was administered intravenously for 1 hour 
without premedication. Dosing and treatment schedules 
were 0.01–5.0 mg/kg once a week (qw), 6.0 mg/kg once 
every 2 weeks (q2w), and 9.0 mg/kg once every 3 weeks 
(q3w). Although this dose-ﬁ  nding study was not designed 
to evaluate efficacy, it was immediately evident that 
panitumumab was active in colorectal cancer, as 5 of the 
6 recorded partial responses were among patients with this 
disease (overall response rate 12.8%). As anticipated, skin-
related events (grade 3/4), a class effect of EGFR inhibitors, 
dominated the observed toxicities. This intensity of rash was 
dose dependent up to 2.0 mg/kg qw. Overall, the grade 3/4 
toxicity rate was 10% and no maximum tolerable dose was Biologics: Targets & Therapy 2008:2(2) 225
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deﬁ  ned. No hypersensitivity reactions or human anti-human 
antibody (HAHA) formation was observed. Pharmacokinetic 
exposure was comparable for all treatment schedules.
The encouraging phase I results led to a phase II trial of 
weekly panitumumab 2.5 mg/kg as monotherapy in previ-
ously treated, refractory patients with metastatic CRC (Malik 
et al 2005). Some patients had received up to 4 lines of prior 
therapy. The study design included 2 cohorts based on EGFR 
staining intensity. A total of 148 patients were treated, with 
15 patients having conﬁ  rmed partial responses (10%) and 
54 patients (36.5%) stable disease. Importantly, these outcomes 
are similar to the results seen with cetuximab monotherapy. 
The median OS was 9.4 months and time to progression 
was 2.5 months. Overall the safety analysis demonstrated 
that panitumumab as monotherapy was well tolerated with 
a grade 3/4 rate of 14% (21 of 148 patients) being registered. 
The most frequently reported grade 3/4 treatment-related 
adverse events were rash (n = 11; 7%), fatigue (n = 4), 
vomiting (n = 2), nausea (n = 1), and pruritus (n = 1). Skin 
toxicity overall was reported in 141 patients (95%; 5% 
grade 3/4), with 2 patients discontinuing treatment. Only 
1 grade 3 infusion-related reaction occurred, which did not 
require dose modiﬁ  cation or treatment interruption.
The pivotal conﬁ  rmation of the earlier observations of 
clinical beneﬁ  t with panitumumab in CRC was a phase III 
trial (Van Cutsem et al 2007b) that randomized 463 meta-
static patients between panitumumab (6.0 mg/kg q2w) and 
best supportive care (n = 231) vs best supportive care alone 
(n = 232). Eligible patients were required (veritable third-
line setting), through prior radiologic conﬁ  rmation, to be 
refractory to ﬂ  uoropyrimidine, irinotecan, and oxaliplatin 
treatment (third-line setting) and to have tumors express-
ing EGFR in  1% of cancer cells examined. The primary 
endpoint of the trial was progression-free survival with 
secondary endpoints including overall survival, objective 
response, and duration of and time to response. The study 
clearly demonstrated superiority of panitumumab over best 
supportive care (BSC) in terms of progression-free survival 
(panitumumab 8 weeks vs BSC 7.3 weeks, hazard ratio (HR) 
of 0.54 (95% CI 0.44, 0.66; p   0.0001). This PFS beneﬁ  t 
though did not translate into an overall survival advantage 
for panitumumab-treated patients (6.5 months for both arms, 
HR 1.00; 95% CI 0.82–1.22; p = 0.81). It is important to 
recognize that the trial allowed patients initially assigned to 
BSC to cross over to receive panitumumab upon progression; 
76% of BSC patients crossed over to receive panitumumab. 
When the hazard ratio was recalculated after censoring for 
patients who crossed over, a modest, but still non-signiﬁ  cant, 
trend in survival was observed (HR 0.78; 95% CI 0.61–1.01). 
Eight percent of patients achieved a response while 28% had 
stable disease. The toxicity proﬁ  le for panitumumab in the 
trial was similar to that in the earlier reported studies.
With the activity of panitumumab in colorectal cancer 
having been conﬁ  rmed, subsequent studies were performed 
to assess the dependence of EGFR expression on clinical 
outcome (Berlin et al 2007; Hecht et al 2007a; Mitchell et al 
2007). Two phase II trials of panitumumab in the third-line 
setting in metastatic CRC patients were conducted that were 
stratiﬁ  ed by EGFR expression. In one trial, the percentage of 
tumor cells positive for EGFR expression had to be negative 
( 1%) or low (1%–9%) and in the other trial, high ( 10%). 
It should be noted that EGFR status was deﬁ  ned by immuno-
histochemical methods which previously were shown to be 
of limited utility in predicting outcome (Chung et al 2005; 
Lenz et al 2006). Patients received at least 2 prior treatment 
regimens consisting of a ﬂ  uoropyrimidine, irinotecan, and 
oxaliplatin. In these studies, patients received 6.0 mg/kg of 
panitumumab q2w until tumor progression or drug intoler-
ability. The primary endpoint of the study was objective 
response which, recently updated after central review, was 
seen in 5% and 8% in the two cohorts, negative/low and 
high, respectively. Only partial responses were seen. Stable 
disease was seen in 30% of all patients (32% negative/low 
EGFR-expression patients and 29% in the high group). 
PFS was 8.0 weeks in both groups. The toxicity proﬁ  le for 
panitumumab was consistent with that of previous reports. 
Dermatologic toxicity of any grade was seen in 93%–97% of 
patients and of grade 3 or higher in 15%–21% of individuals. 
Importantly, 2 panitumumab-related deaths were reported; 
one patient had a pulmonary embolism and another had a 
myocardial infarction and cerebrovascular accident.
Further development of panitumumab required testing 
whether it could be combined with conventional chemotherapy 
agents active in CRC and speciﬁ  cally which agents. A phase 
II trial designed to address this key question incorporated 
panitumumab into irinotecan-containing regimens, either IFL 
or FOLFIRI (Berlin et al 2007). The primary objective was 
to assess the safety of the regimens as ﬁ  rst-line treatment in 
patients with metastatic CRC. Secondary objectives included 
response rate, PFS, and OS. Patients received panitumumab 
(2.5 mg/kg qw × 6) with IFL (irinotecan 125 mg/m2, 
leucovorin 20 mg/m2, and bolus 5-FU 500 mg/m2) or with 
FOLFIRI (irinotecan 180 mg/m2, leucovorin 400 mg/m2, and 
bolus 5-FU 400 mg/m2 followed by a 46-hour infusion of 
5-FU 2,400–3,000 mg/m2 q2w × 3). Patients were required 
to have measurable metastatic CRC, no prior treatment Biologics: Targets & Therapy 2008:2(2) 226
Kim and Grothey
for advanced disease, and EGFR expression in  10% of 
evaluated tumor cells. The objective response rate was 
46% (9 of 19) for patients receiving the panitumumab-IFL 
regimen and 42% (8 of 24) for those receiving panitumumab-
FOLFIRI. The PFS for patients treated with panitumumab 
and either FOLFIRI or IFL were 10.9 months and 5.6 months, 
respectively. The superiority of panitumumab and FOLFIRI 
was not indicative of a speciﬁ  c pharmacologic interaction 
but was attributable to known differences in toxicity and 
survival between the two 5-FU schedules, infusional vs bolus 
administration. The addition of panitumumab to FOLFIRI, 
compared with IFL, was more favorable especially in 
regards to the incidence of grade 3/4 diarrhea (25% vs 58%, 
respectively). Serious adverse events were observed and 
included thromboembolic events – pulmonary embolism 
(3 patients), congestive heart failure, chest pain, and 
significant hypomagnesemia. No infusion reactions or 
panitumumab-induced HAHA formation were reported. 
Overall survival data are not yet available for the trial.
Whether panitumumab could be incorporated into ﬁ  rst-
line treatment regimens for metastatic colorectal patients 
represented the next question, which has been explored in 
a large, multicenter phase III study, the PACCE trial (Pani-
tumumab Advanced Colorectal Cancer Evaluation) (Hecht 
et al 2007b). This study was predicated upon intriguing 
results from the BOND2 trial in which the dual biologic 
approach of bevacizumab combined with cetuximab yielded 
signiﬁ  cant activity in refractory colorectal cancer patients 
(Saltz et al 2007). In order to assess the impact of combin-
ing bevacizumab and cetuximab with front-line standard 
regimens, a larger trial, the US Intergroup (CALGB 80405) 
study, is ongoing. Similarly, the PACCE trial was designed to 
substitute cetuximab with panitumumab and test the biologic 
agents in both oxaliplatin-based (80%) and irinotecan-based 
(20%) regimens. The results from an interim analysis were 
recently presented and included the 812 patients random-
ized to an oxaliplatin-containing regimen and bevacizumab 
without (Arm A) or with panitumumab (Arm B). The pri-
mary endpoint was PFS with secondary endpoints including 
response rate, time to treatment failure, OS, and safety proﬁ  le. 
Standard eligibility criteria were followed; EGFR testing was 
not required. As the trial proceeded, it became apparent that 
the dual biologic-containing Arm B was more toxic than 
the control arm. Speciﬁ  cally, higher grade 4 (28% vs 19%) 
and grade 5 (6% vs 3%) toxicities were seen. In total about 
19% of patients stopped treatment with panitumumab due 
to serious adverse events. In terms of the actual toxicities, a 
higher rate of diarrhea, dehydration, electrolyte imbalance, 
and infections was seen and, when coupled to the known skin 
toxicities, this multitude of side effects created a difﬁ  cult-
to-tolerate regimen. There also was a higher death on study 
rate of 35% (Arm B) vs 27% (Arm A); statistical signiﬁ  cance 
was not reported.
The toxicities and intolerability of the dual biologic 
regimen affected clinical outcomes. No improvement in 
response was seen (Arm A 41% vs Arm B 39%) and, impor-
tantly, the PFS (Arm A 10.5 vs Arm B 9 mos, HR = 1.29, 
95% CI 1.05–1.58) and OS (Arm A not reached vs 
18.6 mos, HR = 1.44, 95% CI 1.10–1.88) were inferior 
as of data cutoff April 2007. In an effort to explain these 
unexpected results, several analyses were performed includ-
ing the amount of exposure patients on study experienced 
to the speciﬁ  c drugs. In the experimental arm, more dose 
delays and reductions were seen especially with the use of 
bolus 5FU. Importantly, the oxaliplatin dose was relatively 
maintained between the two arms (Arm A 88% vs Arm B 
84%). A higher number of patients in the panitumumab-
containing combination discontinued therapy due to pro-
gressive disease than their counterparts (Arm A 27% vs 
Arm B 36%). The investigators summarized that these 
ﬁ  ndings demonstrated an unfavorable therapeutic index 
for the combined biologic regimen due to the reduction 
in PFS and increased toxicity. The question as to whether 
a biological synergy exists between panitumumab and 
bevacizumab or whether toxicity is simply potentiated with 
the combination remains to be answered. At present, data 
from trials combining only the two biologic agents without 
chemotherapy are not available.
The role of panitumumab in the treatment of CRC remains 
to be deﬁ  ned. Despite setbacks, panitumumab may prove 
useful, although further work is required to determine how 
it can be safely combined with standard chemotherapy regi-
mens such as FOLFOX or FOLFIRI. In addition, the setting 
(ﬁ  rst-line, second-line) and the types of patients who beneﬁ  t 
most need further evaluation. Ongoing trials will either 
corroborate or refute the earlier ﬁ  ndings. Toward this end, 
a large European phase III trial is evaluating the combina-
tion of panitumumab and FOLFOX as ﬁ  rst-line therapy in 
patients with metastatic disease. This is an important trial as 
the combination of an oxaliplatin-containing regimen and 
panitumumab deserves to be explored. Another outstanding 
issue is whether the appropriate dose was selected. It needs 
to be highlighted that similar activity has been observed at 
the 6.0 mg/kg q2w vs 2.5 mg/kg qw raising the question of 
whether 5 mg/kg q2w (83% of the present dose) is more 
tolerable.Biologics: Targets & Therapy 2008:2(2) 227
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Panitumumab predicitive markers
In effort to predict which patients will benefit from 
panitumumab, several retrospective analyses have been 
conducted. One consistently interesting observation with 
EGFR inhibitors is that rash intensity correlates with survival 
outcomes (Cunningham et al 2004; Saltz et al 2004). In 
the panitumumab vs BSC trial (Van Cutsem et al 2007b), 
overall survival of patients with grade  2 events is superior 
to that of patients who have grade 1 adverse events (hazard 
ratio, 0.61; 95% CI 0.40–0.95). This observation has been 
consistently reported in trials with EGFR inhibitors reﬂ  ective 
of its being a class effect. In addition, EGFR expression as 
measured by immunohistochemistry (IHC) or ﬂ  uorescence 
in situ hybridization (FISH) is being evaluated although, as 
noted above, the former is not particularly useful (Chung 
et al 2005; Pippas et al 2005).
A more compelling approach to identifying patients who 
will beneﬁ  t from panitumumab is to assess the status of the 
K-ras oncogene. This gene encodes a 21 kDa RAS protein 
which functions as a GTPase involved in signal transduction 
(Bos 1989; Fearon and Vogelstein 1990). Mutations in K-ras 
occur early on in carcinogenesis resulting in constitutively 
activated protein that perpetually drives cellular proliferation. 
In colorectal cancers, K-ras mutations are frequent (20%–
50%), and the great majority of the mutations are clustered in 
two codons, 12 and 13. The utility of K-ras assessment in the 
context of panitumumab monotherapy was recently demon-
strated with archived tissues from the panitumumab vs BSC 
study (Amado et al 2008). Roughly 92% of patients were 
evaluable for K-ras analysis of which 57% were K-ras wild-
type or non-mutated and 43% mutated K-ras. Importantly, 
in the wild-type K-ras patients treated with panitumumab, 
the median PFS was 12.3 vs 7.3 weeks in the BCS-receiving 
patients (HR = 0.45, 95% CI 0.34–0.59, p   0.0001). In the 
mutated K-ras patients, PFS was identical 7.4 vs 7.3 weeks, 
HR = 0.99 (95% CI 0.73–1.36). Even in the K-ras wild-type 
patients who initially were assigned to BSC and later crossed-
over to panitumumab, a better PFS was observed. In addition, 
response rates were 17% in the wild-type K-ras patients and 
0% in their mutated K-ras counterparts.
These types of retrospective analyses allow for 
the prediction of patients most likely to benefit from 
panitumumab and fuel future studies that can prospectively 
examine the true magnitude of this beneﬁ  t. A tantalizing 
hypothesis is that the 40% survival beneﬁ  t seen in WT-ras 
patients with panitumuab can be transferred into the ﬁ  rst-
line setting and rival the survival advantage observed with 
bevacizumab.
Conclusions
Signiﬁ  cant progress in the treatment of colorectal cancer has 
been made as new drugs have proven beneﬁ  cial to metastatic 
colorectal cancer patient. Biologic agents that target speciﬁ  c 
vulnerabilities within cancer cells are amongst these newer 
treatments. The anti-EGFR inhibitor, panitumumab, has 
demonstrable efﬁ  cacy in refractory patients especially in 
regards to PFS. Its utility in other stages of disease and in 
other subsets of patients is under evaluation. The incorpora-
tion of panitumumab into ﬁ  rst- and second-line regimens is 
also currently being tested. In addition, an important predic-
tive biomarker, wild-type K-ras, has been identiﬁ  ed and will 
assist in the pre-selection of patients most likely to beneﬁ  t 
from panitumumab. This type of discovery will eventually 
allow chemotherapy to be tailored to an individual patient, an 
important milestone in the treatment of colorectal cancer.
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